Neonatal thrombocytopenia (NNT) which is frequent in distressed newborns was uncommon in a non-selected population of neonates. The aim of this prospective study was to determine the frequency of NNT and, in confirmed NNT, to search for maternal antiplatelet antibodies with a monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay. Among the 8388 newborns studied, 40 (0.5%, 95% CI 0.3-0.6) had confirmed NNT, which was severe (platelet count < 50 x 10[9]/l) in 10 cases (0.12%, 95% CI 0.05-0.20). Antiplatelet antibodies were detected in 10/31 studied mothers of thrombocytopenic newborns (32.3%): they were alloantibodies in five cases and autoantibodies in five other cases. Among these 10 newborns, seven had severe thrombocytopenia and four had bleeding complications. As controls, antiplatelet antibodies were also searched for in mothers of non-thrombocytopenic newborns: antiplatelet antibodies were present in 8.5% (95% CI 5.9-11.7) of thrombocytopenic mothers (n = 400) and 3.2% (95% CI 0.7-9.0) of non-thrombocytopenic mothers (n = 95). The difference was significant between the control groups and the group of mothers of thrombocytopenic newborns. In conclusion, our data indicate that an immune origin is frequent in NNT and should be looked for, particularly when the platelet count is < 50 x 10(9)/l.
In conclusion, deferiprone and DFO therapy on alternate days may improve compliance with chelation therapy. A negative iron balance can be achieved with this regimen and it may well be cost-effective. A larger prospective randomized study evaluating this model over a longer period of time seems necessary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.